NYSE:RDY - Dr. Reddy's Laboratories Stock Price, Price Target & More

Get Started

$29.11 +0.15 (+0.52 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$28.96

Today's Range$29.02 - $29.25

52-Week Range$28.13 - $42.97

Volume221,500 shs

Average Volume379,998 shs

Market Capitalization$4.78 billion

P/E Ratio28.87

Dividend Yield1.02%

Beta0.25

About Dr. Reddy's Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2017, this segment had 16 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies; and strategic collaboration with Amgen Inc. for the commercialization of oncology and osteoporosis medicines. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:RDY

CUSIPN/A

Webwww.drreddys.com

Phone91-40-4900-2900

Debt

Debt-to-Equity Ratio0.20

Current Ratio1.52

Quick Ratio1.13

Price-To-Earnings

Trailing P/E Ratio28.87

Forward P/E Ratio16.83

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.20 billion

Price / Sales2.19

Cash Flow$2.0328 per share

Price / Cash14.32

Book Value$11.75 per share

Price / Book2.48

Profitability

EPS (Most Recent Fiscal Year)$1.01

Net Income$186 million

Net Margins6.90%

Return on Equity8.69%

Return on Assets4.82%

Miscellaneous

EmployeesN/A

Outstanding Shares165,830,000

Dr. Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced a None dividend on Friday, August 4th. Shareholders of record on Monday, July 17th will be paid a dividend of $0.294 per share on Thursday, August 10th. The ex-dividend date is Thursday, July 13th. View Dr. Reddy's Laboratories' Dividend History.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories (NYSE:RDY) posted its quarterly earnings results on Tuesday, July, 26th. The company reported $0.00 earnings per share (EPS) for the quarter. The company had revenue of $479 million for the quarter, compared to analysts' expectations of $557 million. Dr. Reddy's Laboratories had a net margin of 6.90% and a return on equity of 8.69%. View Dr. Reddy's Laboratories' Earnings History.

When is Dr. Reddy's Laboratories' next earnings date?

Dr. Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Dr. Reddy's Laboratories.

What price target have analysts set for RDY?

3 equities research analysts have issued 1-year target prices for Dr. Reddy's Laboratories' shares. Their forecasts range from $30.51 to $30.51. On average, they anticipate Dr. Reddy's Laboratories' share price to reach $30.51 in the next twelve months. View Analyst Ratings for Dr. Reddy's Laboratories.

Who are some of Dr. Reddy's Laboratories' key competitors?

Some companies that are related to Dr. Reddy's Laboratories include BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Nektar Therapeutics (NKTR), Ono Pharmaceutical (OPHLF), Genmab (GNMSF), Merck Group (MKGAF), Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Sarepta Therapeutics (SRPT).

Who are Dr. Reddy's Laboratories' key executives?

Dr. Reddy's Laboratories' management team includes the folowing people:

Mr. Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.), Co-Chairman, MD & CEO (Age 58)
Mr. Kallam Satish Reddy B.Tech., M.S., Chairman (Age 51)
Mr. Saumen Chakraborty B.Sc. (H), MBA-IIM, Pres, CFO and Global Head of Information Technology & Bus. Process Excellence (Age 57)
Dr. Sripada Chandrasekhar Mba., Ph.D., Pres & Global Head of HR (Age 61)
Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D., Sr. VP & Bus. Head of PSAI Commercial Organization (Age 55)

Has Dr. Reddy's Laboratories been receiving favorable news coverage?

News coverage about RDY stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dr. Reddy's Laboratories earned a media sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the company an impact score of 44.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (3.05%), Royal Bank of Canada (2.45%), Mondrian Investment Partners LTD (0.46%), Dimensional Fund Advisors LP (0.42%), Northern Trust Corp (0.22%) and Senzar Asset Management LLC (0.18%). View Institutional Ownership Trends for Dr. Reddy's Laboratories.

Which major investors are selling Dr. Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Royal Bank of Canada, Citigroup Inc., Zurcher Kantonalbank Zurich Cantonalbank, Sivik Global Healthcare LLC, Aperio Group LLC, Sei Investments Co. and Prudential Financial Inc.. View Insider Buying and Selling for Dr. Reddy's Laboratories.

Which major investors are buying Dr. Reddy's Laboratories stock?

RDY stock was bought by a variety of institutional investors in the last quarter, including Mondrian Investment Partners LTD, Senzar Asset Management LLC, Franklin Resources Inc., Northern Trust Corp, Dimensional Fund Advisors LP, Banco de Sabadell S.A, Commerzbank Aktiengesellschaft FI and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Dr. Reddy's Laboratories.

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $29.11.

How big of a company is Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories has a market capitalization of $4.78 billion and generates $2.20 billion in revenue each year. The company earns $186 million in net income (profit) each year or $1.01 on an earnings per share basis.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]

MarketBeat Community Rating for Dr. Reddy's Laboratories (RDY)

Community Ranking:		2.0 out of 5 ( )
Outperform Votes:		152 (Vote Outperform)
Underperform Votes:		230 (Vote Underperform)
Total Votes:		382

MarketBeat's community ratings are surveys of what our community members think about Dr. Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Dr. Reddy's Laboratories (NYSE:RDY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Dr. Reddy's Laboratories in the last 12 months. Their average twelve-month price target is $30.51, suggesting that the stock has a possible upside of 4.81%. The high price target for RDY is $30.51 and the low price target for RDY is $30.51. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.33	2.25	2.25	2.25
Ratings Breakdown:	1 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$30.51	$30.51	$30.51	$30.51
Price Target Upside:	4.81% upside	16.11% downside	16.11% downside	16.11% downside

Dr. Reddy's Laboratories (NYSE:RDY) Consensus Price Target History

Price Target History for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE:RDY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/1/2017	Jefferies Group	Lower Price Target	Underperform	$31.62 ➝ $30.51	N/A
9/21/2017	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight		Low
8/31/2017	CLSA	Upgrade	Underperform ➝ Outperform		High
5/15/2017	Deutsche Bank	Upgrade	Sell ➝ Hold		High
7/26/2016	Credit Suisse Group	Downgrade	Neutral ➝ Underperform		N/A

(Data available from 5/25/2016 forward)

Dr. Reddy's Laboratories (NYSE:RDY) Earnings History and Estimates Chart

Earnings by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE:RDY) Earnings Estimates

Current Year EPS Consensus Estimate: $1.73 EPS
Next Year EPS Consensus Estimate: $2.07 EPS

Dr. Reddy's Laboratories (NYSE RDY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/26/2018
1/25/2018	Q3 2018		$0.41		$596.00 million	View	N/A
10/31/2017	Q2 2018		$0.26		$543.00 million	View	N/A
7/27/2017	Q1 2018		$0.06		$513.00 million	View	N/A
5/12/2017	Q4 2017		$0.29		$548.00 million	View	N/A
2/4/2017	Q3 2017		$0.42		$546.00 million	View	N/A
10/25/2016	Q2 2017		$0.27		$539.00 million	View	N/A
7/26/2016	Q117		$0.0010	$557.00 million	$479.00 million	View	Listen
5/12/2016	Q416		$0.07	$2.41 billion	$567.00 billion	View	Listen
2/9/2016	Q316		$0.51	$2.48 million	$599.00 million	View	N/A
10/29/2015	Q116		$0.6460	$2.54 billion	$609.00 million	View	Listen
7/30/2015	Q1 2016		$0.58	$611.03 million	$591.00 million	View	N/A
5/12/2015	Q415		$0.49	$559.00 million	$621.00 million	View	Listen
1/29/2015	Q315		$0.53	$561.00 million	$610.00 million	View	N/A
10/29/2014	Q2 2015		$0.54		$579.00 million	View	N/A
7/30/2014	Q115		$0.54	$474.00 million	$486.00 million	View	N/A
5/13/2014	Q414	$0.52	$0.47	$557.00 million	$580.00 million	View	N/A
2/11/2014	Q314	$0.45	$0.59	$558.20 million	$571.00 million	View	N/A
10/31/2013	Q214	$0.46	$0.65	$561.00 million	$537.00 million	View	N/A
7/30/2013	Q413	$0.43	$0.40	$551.40 million	$478.00 million	View	N/A
5/14/2013			$0.60	$635.50 million	$613.00 million	View	N/A
2/14/2013	Q313		$0.40	$505.00 million	$522.00 million	View	N/A
10/30/2012	Q2 2013		$0.58			View	N/A
7/19/2012	Q1 2013		$0.37			View	N/A
5/11/2012	Q4 2012		$0.48			View	N/A
2/3/2012	Q3 2012		$0.60			View	N/A
10/25/2011	Q2 2012		$0.40			View	N/A
7/20/2011	Q1 2012		$0.33			View	N/A
5/13/2011	Q4 2011		$0.37			View	N/A
1/25/2011	Q3 2011		$0.40			View	N/A
10/23/2010	Q2 2011		$0.40			View	N/A
7/22/2010	Q1 2011		$0.30			View	N/A
5/6/2010	Q4 2010		$0.23			View	N/A
1/20/2010	Q3 2010	$0.37	$0.29			View	N/A
10/23/2009	Q2 2010	$0.20	$0.30			View	N/A
7/21/2009	Q1 2010		$0.30			View	N/A
5/18/2009	Q4 2009	$0.33	$0.48			View	N/A
1/20/2009	Q3 2009		$0.20			View	N/A
10/23/2008	Q2 2009		$0.20			View	N/A
7/21/2008	Q1 2009		$0.19			View	N/A
5/20/2008	Q4 2008		$0.15			View	N/A
1/25/2008	Q3 2008		$0.11			View	N/A

(Earnings results data provided by Zacks Investment Research)

Dr. Reddy's Laboratories (NYSE:RDY) Dividend Information

Dr. Reddy's Laboratories pays an annual dividend of $0.29 per share, with a dividend yield of 1.00%. RDY's most recent none dividend payment was Thursday, August 10. Dr. Reddy's Laboratories pays out 28.71% of its earnings out as a dividend.

Most Recent Dividend:	8/10/2017
Annual Dividend:	$0.29
Dividend Yield:	1.00%
Dividend Growth:	0.00% (3 Year Average)
Payout Ratio(s):	28.71% (Trailing 12 Months of Earnings) 16.76% (Based on This Year's Estimates) 14.01% (Based on Next Year's Estimates) 14.27% (Based on Cash Flow)

Dividend Payments by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE:RDY) Dividend History by Quarter

Announced	Period	Amount	Ex-Dividend Date	Record Date	Payable Date
8/4/2017	None	$0.2940	7/13/2017	7/17/2017	8/10/2017
6/6/2017		$0.29	7/13/2017	7/17/2017	7/17/2017
6/6/2016	Annual	$0.2770	7/14/2016	7/18/2016	7/18/2016

(Data available from 1/1/2013 forward)

Dr. Reddy's Laboratories (NYSE RDY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 13.19%

Insider Trading History for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE RDY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Dr. Reddy's Laboratories (NYSE RDY) News Headlines

Source:

Date	Headline
	Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y www.msn.com - May 23 at 4:52 PM
	Dr. Reddy's Laboratories Limited (RDY) CEO G.V. Prasad on Q4 2018 Results - Earnings Call Transcript seekingalpha.com - May 23 at 4:52 PM
	Dr. Reddy’s Q4 and FY18 Financial Results finance.yahoo.com - May 22 at 4:36 PM
	Doctor Reddy's: Fiscal 4Q Earnings Snapshot finance.yahoo.com - May 22 at 9:01 AM
	Dr. Reddy's fourth-quarter profit falls 19 percent on U.S. headwinds finance.yahoo.com - May 22 at 9:01 AM
	India's Dr. Reddy's Q4 profit falls 19 pct on U.S. headwinds finance.yahoo.com - May 22 at 9:01 AM
	What does Dr Reddy’s Laboratories Limited’s (NYSE:RDY) Balance Sheet Tell Us About Its Future? finance.yahoo.com - May 21 at 4:38 PM
	Dr. Reddy's Laboratories (RDY) Set to Announce Quarterly Earnings on Tuesday www.americanbankingnews.com - May 17 at 9:14 AM
	Dr. Reddy's Laboratories (RDY) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - May 11 at 1:28 AM
	Sensex Drops 73 Points; Nifty Ends Above 10700 www.nasdaq.com - May 10 at 9:22 AM
	BRIEF-Dr.Reddy's Labs Gets EIR From USFDA For API Mirfield Plant, UK www.reuters.com - April 25 at 4:50 PM
	Where Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Stands In Terms Of Earnings Growth Against Its Industry finance.yahoo.com - April 23 at 8:55 AM
	Dr. Reddy's Laboratories (RDY) Lowered to "Sell" at BidaskClub www.americanbankingnews.com - April 14 at 9:17 PM
	Dr. Reddy's Laboratories (RDY) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 12 at 5:45 PM
	Dr. Reddy's Laboratories (RDY) Lifted to "Hold" at ValuEngine www.americanbankingnews.com - April 3 at 12:31 AM
	Dr. Reddy's Laboratories (RDY) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 2 at 12:58 PM
	Dr. Reddy's Laboratories (RDY) Price Target Cut to $30.51 by Analysts at Jefferies Group www.americanbankingnews.com - April 2 at 11:16 AM
	Dr. Reddy's Lab and Promius Pharma files NDA for its migraine candidate seekingalpha.com - April 2 at 9:39 AM
	Dr. Reddy's Laboratories (RDY) Announce Filing of NDA for Migraine Candidate www.streetinsider.com - April 2 at 9:39 AM
	Dr. Reddy's Lab announces senior leadership changes seekingalpha.com - March 29 at 9:29 AM
	Asian ADRs Move Sharply Lower in Thursday Trading - Nasdaq www.nasdaq.com - March 22 at 4:46 PM
	Dr. Reddy's Laboratories (RDY) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - March 22 at 1:52 AM
	Asian ADRs Move Sharply Higher in Tuesday Trading - Nasdaq www.nasdaq.com - March 20 at 4:35 PM
	Blog Exposure - Dr. Reddy’s Launches its Levocetirizine Dihydrochloride Tablets in the US Market finance.yahoo.com - March 20 at 9:23 AM
	Dr. Reddy's Laboratories launches Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. market seekingalpha.com - March 17 at 9:21 AM
	New Vernon Capital Holdings II LLC Invests $2.53 Million in Dr.Reddy's Laboratories Ltd (RDY) Stock www.americanbankingnews.com - March 6 at 9:05 AM
	Portland Hill Asset Management Ltd Has $2.10 Million Holdings in Dr.Reddy's Laboratories Ltd (RDY) www.americanbankingnews.com - March 6 at 8:48 AM
	Innoviva (INVA) vs. Dr.Reddy's Laboratories (RDY) Head to Head Comparison www.americanbankingnews.com - March 5 at 5:08 PM
	Dalton Investments LLC Grows Position in Dr.Reddy's Laboratories Ltd (RDY) www.americanbankingnews.com - March 4 at 5:39 AM
	Dr.Reddy's Laboratories Ltd (RDY) Stake Decreased by First Trust Advisors LP www.americanbankingnews.com - March 2 at 8:18 AM
	NINE MASTS CAPITAL Ltd Purchases 33,400 Shares of Dr.Reddy's Laboratories Ltd (RDY) www.americanbankingnews.com - February 27 at 2:30 PM
	Dr.Reddy's Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - February 25 at 1:42 AM
	Financial Contrast: Amicus Therapeutics (FOLD) & Dr.Reddy's Laboratories (RDY) www.americanbankingnews.com - February 12 at 7:22 PM
	Does Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) PE Ratio Warrant A Sell? finance.yahoo.com - February 9 at 9:24 AM
	Indivior sues rivals over Suboxone patents in U.S. www.marketwatch.com - February 8 at 8:44 AM
	Dr.Reddy's Laboratories (RDY) Cut to "Sell" at ValuEngine www.americanbankingnews.com - February 4 at 3:54 PM
	Dr. Reddy's Laboratories Announces the Launch of Tetrabenazine ... - Business Wire (press release) www.businesswire.com - February 2 at 9:21 AM
	Will Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Continue To Underperform Its Industry? finance.yahoo.com - February 1 at 9:25 AM
	Dr.Reddy's Laboratories Ltd (RDY) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - January 31 at 1:52 AM
	FY2018 EPS Estimates for Dr.Reddy's Laboratories Ltd Reduced by Jefferies Group (RDY) www.americanbankingnews.com - January 30 at 10:54 AM
	Doctor Reddy's posts 3Q profit finance.yahoo.com - January 25 at 9:21 AM
	Dr. Reddy’s Q3 and 9M FY18 Financial Results finance.yahoo.com - January 25 at 9:21 AM
	Dr.Reddy's Laboratories (RDY) to Release Quarterly Earnings on Thursday www.americanbankingnews.com - January 18 at 2:50 AM
	Dr. Reddy's to release Q3 FY18 results on January 25, 2018 finance.yahoo.com - January 16 at 8:33 AM
	Dr. Reddy's Laboratories Limited to Present at the 36th Annual JP Morgan Healthcare Conference - Business Wire (press release) www.businesswire.com - January 6 at 3:26 PM
	Dr.Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - January 6 at 1:26 AM
	Asian ADRs Move Higher in Tuesday Trading - Nasdaq.com - Nasdaq www.nasdaq.com - January 2 at 3:32 PM
	Dr.Reddy's Laboratories (RDY) Upgraded to Hold at Zacks Investment Research www.americanbankingnews.com - January 2 at 12:00 PM
	Bullish Two Hundred Day Moving Average Cross - RDY - Nasdaq.com - Nasdaq www.nasdaq.com - December 30 at 3:26 PM
	Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend? finance.yahoo.com - December 30 at 8:40 AM

Dr. Reddy's Laboratories (NYSE:RDY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Dr. Reddy's Laboratories (NYSE:RDY) Income Statement, Balance Sheet and Cash Flow Statement

Dr. Reddy's Laboratories (NYSE RDY) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff